PMID- 34082439
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1698-6997 (Electronic)
IS  - 1139-6121 (Linking)
VI  - 23
IP  - 3
DP  - 2021 Jun 3
TI  - Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients 
      with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials.
PG  - 133-142
LID - 10.24875/AIDSRev.20000103 [doi]
AB  - A new strategy of simplification therapy shown the unique benefits in clinical 
      treatment, by reducing pill burden and avoid drug exposure. To provide more 
      evidence for the strategy, we compared the efficacy and safety of dolutegravir 
      (DTG)-containing simplified dual combination antiretroviral therapy (cART) and 
      traditional triple cART for people living with HIV/AIDS. The meta-analysis of 
      randomized controlled trials compared DTG-containing dual therapy with triple 
      cART. The primary outcome was virologic suppression. The secondary outcomes 
      included CD4T cell recovery, lipids change from baseline, and adverse events 
      (AEs). A total of 7 studies, 4852 patients were eligible, 2423 (49.9%) received 
      DTG-based simplified dual cART, and 2429 (50.1%) received triple cART. The viral 
      suppression rate was 94.7% at 24 weeks, 93.0% at 48 weeks, and 96.6% at 96 weeks 
      in dual cART. The viral suppression rate of dual cART was non-inferior to triple 
      cART at 24 weeks (risk difference [RD], -0.00; 95% confidence interval [CI] 
      -0.02-0.01), at 48 weeks (RD, -0.01; 95% CI -0.02-0.01), and at 96 weeks (RD, 
      -0.01; 95% CI -0.02-0.00). Sub-analysis results were consistent with the overall 
      results. With regard to other outcomes (CD4T counts, lipids, any AEs, and AEs 
      grade >/= 3), there was no significant statistical difference between the two 
      regimens. DTG-based simplified dual cART was non-inferior to triple cART in terms 
      of efficacy and safety. This finding provides strong support for current 
      consensus guidelines recommended the dual regimen as first-line treatment.
FAU - Shu, Yuanlu
AU  - Shu Y
AD  - Department of Evidence-based Medicine and Clinical Center, The First People's 
      Hospital of Huaihua, University of South China, Huaihua, China.
FAU - Qiu, Chengfeng
AU  - Qiu C
AD  - Department of Evidence-based Medicine and Clinical Center; Department of Clinical 
      Pharmacy; The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
FAU - Tu, Xiaojun
AU  - Tu X
AD  - Department of Evidence-based Medicine and Clinical Center, The First People's 
      Hospital of Huaihua, University of South China, Huaihua, China.
FAU - Deng, Ziwei
AU  - Deng Z
AD  - Department of Evidence-based Medicine and Clinical Center; Department of Clinical 
      Pharmacy; The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
FAU - Deng, Ye
AU  - Deng Y
AD  - Department of Evidence-based Medicine and Clinical Center; Department of Clinical 
      Pharmacy; The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
FAU - Wang, Hongqiang
AU  - Wang H
AD  - Department of Evidence-based Medicine and Clinical Center; Department of Clinical 
      Pharmacy; The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
FAU - Zhao, Xiang
AU  - Zhao X
AD  - Department of Evidence-based Medicine and Clinical Center; Department of General 
      Practice, The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
FAU - Shi, Zhihua
AU  - Shi Z
AD  - Department of Evidence-based Medicine and Clinical Center; Department of Clinical 
      Pharmacy; The First People's Hospital of Huaihua, University of South China, 
      Huaihua, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210603
PL  - Spain
TA  - AIDS Rev
JT  - AIDS reviews
JID - 101134876
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - DKO1W9H7M1 (dolutegravir)
SB  - IM
MH  - *Anti-HIV Agents/adverse effects
MH  - *HIV Infections/drug therapy
MH  - *HIV-1
MH  - Heterocyclic Compounds, 3-Ring/adverse effects
MH  - Humans
MH  - Oxazines/therapeutic use
MH  - Piperazines/therapeutic use
MH  - Pyridones/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Viral Load
OTO - NOTNLM
OT  - Dolutegravir
OT  - Dual therapy
OT  - Meta-analysis
OT  - Efficacy
OT  - Safety
EDAT- 2021/06/04 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/06/03 20:31
PHST- 2021/06/03 20:31 [entrez]
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.24875/AIDSRev.20000103 [doi]
PST - epublish
SO  - AIDS Rev. 2021 Jun 3;23(3):133-142. doi: 10.24875/AIDSRev.20000103.